- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00299338
A Dose Response and Safety Study of Procaine HCl in HIV-Infected Patients
A Pharmacokinetic and Safety Study of Procaine HCl in HIV-1 Infected Patients
Visão geral do estudo
Descrição detalhada
STUDY PLAN: DESCRIPTION This investigation will be a non-randomized, open-label study of four doses of SP01A in 24 individuals infected with HIV who are being treated with triple combination antiretroviral therapy. Additionally, a group of six HIV-negative subjects (group E) is being recruited as a control for cortisol secretion. This group will not receive study medication nor will they be evaluated for dose response or safety parameters.
DISCUSSION OF STUDY DESIGN, INCLUDING CONTROL GROUP Patients will receive the following doses of SP01A and will be divided into a low dose and high dose group for further analyses. There will be two segments within the low dose group. Group A will receive 200 mg of SP01A once per day. Group B will be administered 200 mg of SP01A twice daily. Similarly, there will be two segments in the high dose group. Group C will be treated with 200 mg of SP01A three times per day, while Group D will be administered 400 mg of SP01A twice daily.
A fifth group will also be introduced. This group, Group E, will serve as a control group and not receive any treatment.
The study will be conducted at a single investigative center (AIDS ReSearch Alliance, West Hollywood, CA). Six subjects with a diagnosis of HIV who are also receiving triple combination antiretroviral therapy and have been so doing for a minimum of 2 months are planned per group. Patients will be admitted to an in-patient facility for 72 hours. After an initial night to acclimate the patients to the facility, a 24-hour measurement of cortisol secretion in blood and urine will be conducted. After this is complete, patients will receive an initial single dose of SP01A orally. (200 mg SP-01A for group A, 400 mg for group B, 600 mg for group C, and 800 mg for group D). Blood and urine samples will also be collected for 24 hours to further evaluate the safety of the study medication. Patients will then be discharged from the facility.
After a 4-day washout, patients will return to the facility to start an 8-week dose-response study, sequentially using the four doses that will now be divided (200 mg daily for group A, 200 mg twice a day for group B, 200 mg three times per day for group C, and 400 mg twice daily for group D).
Subjects will return to the study center the day they are screened and as close to the same day of the week as practical during Weeks 1 (baseline), 2, 3, 4, 5, 6, 7, 8 (end of treatment) and 10 (post-treatment for examinations and specimen collection, as well as evaluation of reactions to study treatment). At the end of the 8-week drug administration period, patients will again be admitted to an in-patient facility for 72 hours. As before, patients will have an initial night to acclimate to the facility, followed by a 24-hour measurement of cortisol secretion in blood and urine. In the morning, following and ending the 24 hour basal cortisol secretion, patients in the four successive groups (A, B, C, and D), will receive their last dose of medication. They will also give their last blood and urine samples over the next 24 hours for additional safety sample collection. The total duration of study subject participation will be 11 weeks.
The six HIV negative subjects will be enrolled in group E. After an initial night to acclimate to the facility, blood and urine samples will be collected to determine baseline 24 hour blood and urine cortisol secretion. Patients will then be discharged. No study medication will be given to patients in group E.
Tipo de estudo
Inscrição
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
California
-
West Hollywood, California, Estados Unidos, 90069
- AIDS Research Alliance of West Hollywood
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Eighteen years of age or older (male or female).
- If female, agreed to use suitable contraception to prevent pregnancy.
- HIV positive as confirmed by viral load using nucleic acid sequence based amplification (NASBA), or enzyme-linked immunosorbent assay (ELISA) and Western Blot, for cohort A, B, C, and D. HIV negative by ELISA and Western blot for cohort E.
- Karnofsky Performance Status score of at least 60.
- No active opportunistic infection. Prophylaxis for MAl, CMV, Pneumocystis Pneumonia except Bactrim), or herpes was permitted.
- Current CD4 count >200.
- Stable triple therapy antiretroviral regimen (cohorts A, B, C, and D) for the preceding 8 weeks and willing to make no changes in regimen during the study.
- Not taking any unapproved or experimental treatment for HIV, including antiretrovirals and immune modulators (such as interferons or interleukins).
- Capable and willing to provide informed consent.
- Agreed not to take Epoetin during the trial.
- Baseline laboratory values:
Neutrophils > 1000 cells/mm3; Platelets > 75,000 cells/mL; SGOT <3 times upper limit of normal; SGPT <3 times upper limit of normal; Creatinine <2.0 mg/dL.
Exclusion Criteria:
- Known or suspected allergy to procaine hydrochloride.
- Patients taking DHEA supplementation or oral ketoconazole (which have anticortisol properties).
- Patients using sulfonamides (including Septra/Bactrim).
- Required use of sulfonamides, eg, Septra/Bactrim. (Procaine hydrochloride may inactivate sulfonamides).
- Patients with glaucoma using anti-cholinesterase inhibitors (Humorsol [demecarium bromide] echothiophate iodide, Floropryl [isoflurophate], Isopto-Eserine [physostigmine salicylate]). Anti-cholinesterase Inhibitors should not be used while on procaine hydrochloride, since procaine itself has some anti-cholinesterase activity.
- Patients with less than 6 months life expectancy.
- Patients with adrenal insufficiency (determined by screening ACTH stimulation test).
- Patients with lymphoma.
- Patients with active hepatitis (viral or drug induced).
- Patients with cancer, except peripheral Kaposi's sarcoma.
- Patients on dialysis.
- Patients who are pregnant.
- Female patients of childbearing age who can not use two forms of birth control or abstain from sexual intercourse during the trial.
- Any medical, psychological, psychiatric, or substance use problem that, in the opinion of the Principal Investigator, interferes with the patient's ability to complete the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
---|
Mean viral load reduction (log10) over 8 weeks
|
Maximal viral load suppression (LDL <50 & 400) over 8 weeks
|
Cortisol reduction over 8 weeks
|
Medidas de resultados secundários
Medida de resultado |
---|
Improvement in quality of life indices (Whalen Scale) over 8 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Stephen J Brown, MD, AIDS Research Alliance of West Hollywood
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Infecções por vírus de RNA
- Doenças Virais
- Infecções
- Infecções transmitidas pelo sangue
- Doenças Transmissíveis
- Doenças Sexualmente Transmissíveis, Virais
- Doenças Sexualmente Transmissíveis
- Infecções por Lentivírus
- Infecções por Retroviridae
- Síndromes de Deficiência Imunológica
- Doenças do sistema imunológico
- Infecções por HIV
Outros números de identificação do estudo
- SP01A-SII-101
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Infecções por HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecrutamentoHIV | Teste de HIV | Ligação do HIV ao Cuidado | Tratamento de HIVEstados Unidos
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement e outros colaboradoresDesconhecidoHIV | Crianças não infectadas pelo HIV | Crianças expostas ao HIVCamarões
-
University of MinnesotaRetiradoInfecções por HIV | HIV/AIDS | HIV | AUXILIA | Aids/problema de HIV | AIDS e InfecçõesEstados Unidos
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationConcluídoTeste de HIV do parceiro | Aconselhamento de casal HIV | Comunicação de casal | Incidência de HIVCamarões, República Dominicana, Geórgia, Índia
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... e outros colaboradoresRecrutamentoHIV | Teste de HIV | Vinculação ao cuidadoÁfrica do Sul
-
CDC FoundationGilead SciencesDesconhecidoProfilaxia pré-exposição ao HIV | Quimioprofilaxia HIVEstados Unidos
-
Erasmus Medical CenterAinda não está recrutandoInfecções por HIV | HIV | Infecção por HIV-1 | Infecção HIV IHolanda
-
Helios SaludViiV HealthcareDesconhecidoHIV | Infecção por HIV-1Argentina
-
National Taiwan UniversityRecrutamento
-
University of Maryland, BaltimoreRetiradoHIV | Transplante de rim | Reservatório de HIV | CCR5Estados Unidos